Leal, L.; Fehér, C.; Richart, V.; Torres, B.; GarcÃa, F.
Antiretroviral Therapy Interruption (ATI) in HIV-1 Infected Patients Participating in Therapeutic Vaccine Trials: Surrogate Markers of Virological Response. Vaccines 2020, 8, 442.
https://doi.org/10.3390/vaccines8030442
AMA Style
Leal L, Fehér C, Richart V, Torres B, GarcÃa F.
Antiretroviral Therapy Interruption (ATI) in HIV-1 Infected Patients Participating in Therapeutic Vaccine Trials: Surrogate Markers of Virological Response. Vaccines. 2020; 8(3):442.
https://doi.org/10.3390/vaccines8030442
Chicago/Turabian Style
Leal, Lorna, Csaba Fehér, Valèria Richart, Berta Torres, and Felipe GarcÃa.
2020. "Antiretroviral Therapy Interruption (ATI) in HIV-1 Infected Patients Participating in Therapeutic Vaccine Trials: Surrogate Markers of Virological Response" Vaccines 8, no. 3: 442.
https://doi.org/10.3390/vaccines8030442
APA Style
Leal, L., Fehér, C., Richart, V., Torres, B., & GarcÃa, F.
(2020). Antiretroviral Therapy Interruption (ATI) in HIV-1 Infected Patients Participating in Therapeutic Vaccine Trials: Surrogate Markers of Virological Response. Vaccines, 8(3), 442.
https://doi.org/10.3390/vaccines8030442